NCT05038748

Brief Summary

The primary aims are to identify important gut microbiota signatures for youth with ASD, to identify dysbiosis features for different levels of ASD features and clinical courses, to search the possibility to intervene the disease course if we can tease out the dysbiosis responsible for the flare-up and improvement of the symptoms of the disease. The secondary aims are to identify the clinical and neuropsychological measures that are associated with direct and indirect regulation or interactions from gut-brain axis signaling, and based our preliminary results on reducing the measures for future large-scale microbiome study in ASD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

September 1, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 9, 2021

Completed
Last Updated

September 16, 2021

Status Verified

January 1, 2021

Enrollment Period

2 years

First QC Date

September 1, 2021

Last Update Submit

September 8, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Autism Diagnostic Interview-Revised (ADI-R)

    Including reciprocal social interaction, communication, and repetitive behaviors and stereotyped patterns, for children with a mental age from about 18 months into adulthood. The coding of some items is converted to numeric scores "0" if no evidence of abnormality exists, "1" if some evidence of abnormality exists, and "2" if evidence of marked abnormality. Higher scores mean more severe clinical deficits.

    1 hour

  • Autism Diagnostic Observation Scale (ADOS)

    Including communication, social interaction, creativity, stereotyped behaviors and restricted interests. The coding of some items is converted to numeric scores "0" if no evidence of abnormality exists, "1" if some evidence of abnormality exists, and "2" if evidence of marked abnormality. Higher scores mean more severe clinical deficits.

    1 hour

Study Arms (3)

ASD group

80 youths with the clinical diagnosis of ASD according to the DSM-5 diagnostic criteria

Other: Psychiatric diagnosisOther: ASD diagnosis

Sibling group

30 unaffected siblings of ASD youths

Other: Psychiatric diagnosis

TD group

40 healthy typical developing(TD) control from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007

Other: Psychiatric diagnosis

Interventions

Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

ASD groupSibling groupTD group

Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)

ASD group

Eligibility Criteria

Age7 Years - 25 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The cohort was established at the Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.

You may qualify if:

  • a clinical diagnosis of ASD defined by the DSM-IV confirmed by ADI-R or ADOS and also clinical reappraisal based on the newly release DSM-5 criteria for ASD
  • ages range from 7 to 25 at the time now
  • at least one biological parent
  • parents that are both Han Chinese in Taiwan

You may not qualify if:

  • intellectual disability
  • epilepsy
  • ADHD
  • autoimmune diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan Univeristy Hospital

Taipei, Taiwan

Location

Biospecimen

Retention: SAMPLES WITH DNA

5 g of stool sample

MeSH Terms

Conditions

Autism Spectrum Disorder

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 1, 2021

First Posted

September 9, 2021

Study Start

January 1, 2019

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

September 16, 2021

Record last verified: 2021-01

Locations